Please enter your username and password below, if you are not yet a member of Oncology Central remember you can register for free.
Already have an account? Login here
Categories // Subject Area // Lung
Five-year data from the Phase 1B KEYNOTE-001 clinical trial has demonstrated that pembrolizumab increases overall survival for advanced non-small-cell lung patients (aNSCLC).
It's completely free
Written ByJade Parker, Senior Editor